Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...

Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025. Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the ...

A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, ...

The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Sanofi has received U.S. Food and Drug Administration (FDA) approval for Merilog (insulin-aspart-szjj), a biosimilar to ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...